Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
Author: ["Julie M. Wilson","Kathryn S. Kalasinsky","Allan I. Levey","Catherine Bergeron","Gregory Reiber","Robert M. Anthony","Gregory A. Schmunk","Kathleen Shannak","John W. Haycock","Stephen J. Kish"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Methamphetamine is a drug that is significantly abused worldwide. Although long–lasting depletion of dopamine and other dopamine nerve terminal markers has been reported in striatum of nonhuman primates receiving very high doses of the psychostimulant1–3, no information is available for humans. We found reduced levels of three dopamine nerve terminal markers (dopamine, tyrosine hydroxylase and the dopamine transporter) in post–mortem striatum (nucleus accumbens, caudate, putamen) of chronic methamphetamine users. However, levels of DOPA decarboxylase and the vesicular monoamine transporter, known to be reduced in Parkinson's disease4,5, were normal. This suggests that chronic exposure to methamphetamine does not cause permanent degeneration of striatal dopamine nerve terminals at the doses used by the young subjects in our study. However, the dopamine reduction might explain some of the dysphoric effects of the drug, whereas the decreased dopamine transporter could provide the basis for dose escalation occurring in some methamphetamine users.
Cite this article
Wilson, J., Kalasinsky, K., Levey, A. et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2, 699–703 (1996). https://doi.org/10.1038/nm0696-699
